Investigation of the antibiotic susceptibility patters of pathogens causing nosocomial infections

Saudi Medical Journal

Volumn 25, Issue 10, 2004, Pages 1403-1409

  Yaman, Akgun ^a   Tasova, Yesim ^a   Kibar, Filiz ^a   Inal, Ayse S ^a   Saltoglu, Nese ^a   Buyukcelik, Ozlem ^a   Kurtaran, Behice ^a   Dundar, Ismail H ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ACINETOBACTER; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CITROBACTER; CONTROLLED STUDY; ENTEROBACTER; ENTEROCOCCUS; ENZYME SYNTHESIS; ESCHERICHIA COLI; FOLLOW UP; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS; STREPTOCOCCUS; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; COHORT STUDIES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TURKEY;

EID: 7244245748     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Turner PJ. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) Program a global overview. J Antimicrob Chemother 2000; 46: 9-23.
2. Pfaller MA, Jones RN. For the MYSTIC Study Group (Americas) results from the Americas resistance implications in the treatment of serious. J Antimicrob Chemother 2000; 46: 25-37.
3. Jones RN. MYSTIC Advisory Board Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility between countries and center types. J Antimicrob Chemother 2000; 46: 1-8.
4. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDS definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-140.
5. Horan TC, Gaynes RP, Mortane WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC defitinitons of surgical wound infections. Am J Infect Control 1992; 20: 271-274.
6. National Committee for Clinical Laboratory Standards (NCCLS). Performance standard for antimicrobial susceptibility testing. Eleventh informational Supplement. Document M100-S11. Wayne (PA): NCCLS; 2001
7. David M, Livermore-Derek FJ, Brown DF. Detection of b-lactamase-mediated resistance. J Antimicrob Chemother 2001; 48: 59-64.
8. Mendes C, Hsiung A, Kiffer C, Oplustil C, Sinto S, Mimical I et al. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial surveillance Program. Braz J Infect Dis 2000; 4: 236-244.
9. Goossens H. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. J Antimicrob Chemother 2000; 46: 39-52.
10. Goossens H, MYSTIC Study Group (Europe). MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis 2001; 41: 183-189.
11. Fluit AC, Verhoef J, Schmitz FJ, European SENTRY Participants. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY antimicrobial Surveillance Program 1997-1998. Eur J Clin Microbiol Infect Dis 2001; 20: 617-625.
12. Fontana R, Lo Cascio G, Giacobone E, Romero E, Cipriani P, Sessa R, et al. Resistance surveillance in Italy: four-year results from the MYSTIC program. J Chemother 2002; 14: 323-331.
13. Pfaller MA, Jones RN, Biedenbach DJ, MYSTIC Study Group (Europe). Antimicrobial resistance trends in medical centers using carbapeneme: report or 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis 2001 ; 41:177-182.
14. Garcia-Rodriguez JA, Jones RN, MYSTIC Programme Study Group. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meopenem Yearly Susceptibility Test Information Collection (MYSTIC) programme. J Chemother 2002; 14: 25-32.
15. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoll C, Barth A, et al. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobical Surveillance Program. Braz J Infect Dis 2001; 5: 200-214.
16. Aksaray S, Dokuzoguz B, Guvener E, Yucesoy M, Yulug N, Kocagoz S, et al. Surveillance of antimicrobial resistance among Gram-negative isolates from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother 2000; 45: 695-699.
17. Turner PJ, Greenhalgh JM, The MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 19007-2000. Clin Microbiol Infect 2003; 9: 563-567.
18. Gunseren F, Mamikoglu L, Ozturk S, Yucesoy M, Biberoglu K, Yulug N, et al. A surveillance study of antimicrobial resistance of Gram-negative bacteria isolated from intensive care units in eight hospital in Turkey. J Antimicrob Chemother 1999; 43: 373-378.
19. Mendes C, Turner PJ, MYSTIC Study Group (Europe). Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-200). Diagn Microbiol Infect Dis 2001; 41: 191-196.
20. Johnson DM, Biedenbach DJ, Jones RN. In vitro evaluation of broad-spectrum beta-lactams in the Philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999; 35: 291-297.
21. Goossens H. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic suspectibilities between countries and centre type. MYSTIC Study Group (European centres only). J Antimicrob Chemother 2000; 46: 39-52.
22. Kocazeybek BS. Antimicrobial resistance surveillance of gram-negative bacteria isolated from intensive care units of four different hospitals in Turkey. Evaluation of the prevalence of extended-spectrum and inducible beta-lactamases using different E-test strips and direct induction methods. Chemother 2001; 47: 396-408.
23. Leblebicioglu H, Gunaydin M, Esen S, Tuncer I, Findik D, Ural O, et al. Surveillance of antimicrobial resistance in gram-negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J Chemother 2002; 14: 140-146.
24. Jones RN, Rhomberg PR, Varnam DJ, Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-durg resistant Gram-negative bacilli including bacteraemic Salmonella spp.: Initial studies for the MYTIC programme in India. Int J Antimicrob Agents 2002; 20: 426-431.
25. Jones RN, Jenkins SG, Hoban DJ, Pfaller MA, Ramphal R. In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. Int J Antimicrob Agents 2000; 15: 111-118.
26. Sader HS, Jones RN, Andrade-Baiocchi S, Biedenbach DJ. SENTRY Participants. Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn Microbiol Infect Dis 2002; 44: 273-280.
27. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN; Sentry APAC Study Group. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pasific region and South Africa: regional results from SENTRY Antimicrobial Suveillance Program (1998-99). Diagn Microbiol Infect Dis 2002; 42: 193-198.
28. Biedenbach DJ, Johnson DM, Jones RN. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999; 35: 299-305.
29. Lewis MT, Biedenbach DJ, Jones RN. In vitro evaluation of cefepime and other broad-spectrum beta-lactams bacteria from Indonesian medical centers. The Indonesia Antimicrobial Study Group. Diagn Microbiol Infect Dis 1999; 35: 285-290.
30. Pfaller MA, Jones RN, Doern GV, Salazar JC. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia: comparison of data from 1997 and 1998 using the E-test method. The Colombian Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999; 35: 235-241.
31. Pfaller MA, Jones RN, Doern GV. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela: comparison of data from 1997 and 1998 using the E-test method. Venezuelan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999; 35: 153-158.
32. Aktas E, Yigit N, Yazgi H, Ayyildiz A. Detection of antimicrobial and extended-spectrum beta-lactamase production in Klebsiella pneumoniae strains from infected neonates. J Int Med Res 2002; 30: 541.
33. Johnson DM, Biedenbach DJ, Jones RN. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 2002; 43: 49-60.
34. Pfaller MA, Jones RN, MYSTIC Study Group (Europe). Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information. Collection (MYSTIC) Programmed, Europe 1997-2000. Int J Antimicrob Agents 2002; 19: 383-388.